US equities
|
MU
$1,048.27
▼-1.58%
NVDA
$230.19
▲+0.79%
SNDK
$1,727.91
▼-0.69%
TSLA
$356.82
▲+0.57%
INTC
$119.30
▼-0.77%
AMD
$609.90
▼-0.30%
GOOGL
$340.53
▼-1.03%
LITE
$1,067.41
▲+9.90%
MU
$1,048.27
▼-1.58%
NVDA
$230.19
▲+0.79%
SNDK
$1,727.91
▼-0.69%
TSLA
$356.82
▲+0.57%
INTC
$119.30
▼-0.77%
AMD
$609.90
▼-0.30%
GOOGL
$340.53
▼-1.03%
LITE
$1,067.41
▲+9.90%
FinancialContent
Watchlist
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
My watchlist
My portfolio
Recent quotes
Articles published by Endospan
Endospan Announces Closing of Acquisition by Artivion, Inc., Following FDA PMA Approval of the NEXUS® Aortic Arch System
May 18, 2026
From
Endospan
Via
Business Wire
Tickers
AORT
Endospan Receives FDA Approval for the NEXUS® Aortic Arch Stent Graft System
April 07, 2026
From
Endospan
Via
Business Wire
Endospan Announces Positive One-Year Data from TRIOMPHE FDA Pivotal Study For the NEXUS® Aortic Arch Stent-Graft System
February 03, 2026
From
Endospan
Via
Business Wire
Endospan Announces Positive 30-Day Data from TRIOMPHE FDA Clinical Study of NEXUS® Aortic Arch Stent-Graft
May 05, 2025
From
Endospan
Via
Business Wire
Endospan Completes Enrollment of Primary Arm in NEXUS® Aortic Arch Stent Graft TRIOMPHE IDE Clinical Study
October 21, 2024
From
Endospan
Via
Business Wire
Endospan Releases Early TRIOMPHE IDE Study Results at Society of Thoracic Surgeons
January 30, 2024
From
Endospan
Via
Business Wire
Endospan Announces Initial Experience with the Custom-Made NEXUS DUO™ Aortic Arch Stent Graft System
June 19, 2023
From
Endospan
Via
Business Wire
Endospan Reports Landmark Publication on the Initial Experience With the NEXUS™ Aortic Arch Stent Graft System
November 01, 2021
From
Endospan
Via
Business Wire